Mesa Laboratories, Inc.
NASDAQ:MLABHardware, Equipment & Parts
-$0.15 today
- Market cap
- $774.56M
- Beta
- 0.93
- P/E (TTM)
- 78.3
- EPS (TTM)
- $1.21
- Dividend yield
- 0.68%
Volume 0.07M
Average 0.16M
MLAB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Mesa Laboratories, Inc.NASDAQ: MLAB
Research & Development · Q4 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q4 FY2026 research & development of $5.25M rose 3.0% year over year, behind the +4.0% change in trailing-twelve-month research & development. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Research & development amounted to 8.2% of revenue in FY2026, unchanged from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +3.0% toward the trailing-twelve-month pace of +4.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 20.31M USD
- Year-over-year change
- +4.0%
- 4-year CAGR
- +6.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 20.31M | +4.0% |
| FY2025 | 2025-03-31 | 19.52M | +1.1% |
| FY2024 | 2024-03-31 | 19.3M | -5.8% |
| FY2023 | 2023-03-31 | 20.49M | +30.0% |
| FY2022 | 2022-03-31 | 15.77M | — |
Research & Development vs competitors
How MLAB compares with its peers on the latest reported figures
- MLAB's LTM Mar 2026 research & development of $20.31M is the lowest of the 11 companies compared; the peer median is $205.25M.
- Its year-over-year change of +4.0% is the 5th highest of 11, against a peer median of -1.9%.
- Research & development amounts to 8.2% of revenue for MLAB, versus a peer median of 9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jul 2026 | $485M | +8.5% | -0.9% | 6.6% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Sep 2026 | $222.54M | -10.9% | -3.5% | 36.0% | |
| LTM Jul 2026 | $215.83M | +5.2% | -0.9% | 7.4% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Mar 2026 | $87.86M | -27.1% | -20.4% | 54.9% | |
| LTM Mar 2026 | $22.48M | -43.6% | -11.4% | 26.1% | |
| LTM Jun 2026 | $21.15M | +13.2% | +8.3% | 10.1% | |
| LTM Mar 2026 | $20.31M | +4.0% | -0.3% | 8.2% | |
| Peer median (excluding MLAB) | $205.25M | -1.9% | -0.9% | 9.7% | |
Competitors are the stored peer set for MLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 184.34M | 219.08M | 216.19M | 240.98M | 249.13M |
| Cost of Revenue | 75.25M | 85.39M | 82.94M | 90.11M | 90.86M |
| Gross Profit | 109.09M | 133.69M | 133.25M | 150.87M | 158.27M |
| Gross Margin | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Research & Development | 15.77M | 20.49M | 19.3M | 19.52M | 20.31M |
| Selling, General & Admin | 88.62M | 109.88M | 111.49M | 115.02M | 119.45M |
| Operating Expenses | 104.39M | 130.37M | 405.33M | 134.53M | 139.76M |
| Depreciation & Amortization | 25.07M | 33.13M | 31.57M | 24.53M | 23.27M |
| EBITDA | 32.53M | 37.52M | (238.38M) | 42.35M | 35.29M |
| EBITDA Margin | 17.6% | 17.1% | -110.3% | 17.6% | 14.2% |
| Operating Income | 4.7M | 3.32M | (272.08M) | 16.34M | 18.51M |
| Operating Margin | 2.6% | 1.5% | -125.9% | 6.8% | 7.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.89M | 4.77M | 5.7M | 11.86M | 10.69M |
| Other Income / Expenses | (1.13M) | (3.71M) | (3.57M) | (10.38M) | (6.5M) |
| Income Before Tax | 3.57M | (389K) | (275.65M) | 5.96M | 12.01M |
| Pre-Tax Margin | 1.9% | -0.2% | -127.5% | 2.5% | 4.8% |
| Income Tax Expense | 1.7M | (1.32M) | (21.4M) | 7.94M | 5.3M |
| Net Income | 1.87M | 930K | (254.25M) | (1.97M) | 6.71M |
| Net Margin | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
| EPS (Basic) | 0.36 | 0.17 | (47.20) | (0.36) | 1.22 |
| EPS (Diluted) | 0.35 | 0.17 | (47.20) | (0.36) | 1.21 |
| Weighted Avg Shares | 5.21M | 5.32M | 5.39M | 5.43M | 5.51M |
| Weighted Avg Shares (Diluted) | 5.34M | 5.36M | 5.39M | 5.43M | 5.57M |
Mesa Laboratories, Inc.
NASDAQ:MLAB
Intrinsic Alpha fair value
Locked
Current Price
$137.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.